Date:
December 28, 2020
Issue #:
1614
Summary:
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
